MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus by Mohammadpour, Mehrdad et al.
Original Article
MyoRing Implantation with and without Corneal
Collagen Crosslinking for the Management of
Keratoconus
Mehrdad Mohammadpour, MD; Ahmad Masoumi, MD; Mahmoud Dehghan, MD
Mohammad Nasser Hashemian, MD; Shahab Addin Karami, MD
Alireza Mahmoudi, MD





Purpose: To evaluate the safety and efficacy of femtosecond laser-assistedMyoRing implantation
with concurrent corneal collagen crosslinking (CXL) compared to MyoRing alone for the treatment
of progressive keratoconus.
Methods: A total of 60 patients were enrolled in this randomized controlled trial. The patients
were randomly allocated into two groups. In the first group, MyoRing was implanted, while in the
second, it was inserted in the corneal stroma using the same technique, along with simultaneous
CXL. Visual, refractive, topographic, and abberometric outcomes were measured preoperatively
and at every postoperative visit.
Results: Data of 47 patients were available at the end of the study; 28 in the MyoRing group and
19 in the MyoRing + CXL group. The mean uncorrected distance visual acuity (UDVA) improved
from 0.79 ± 0.39 logMAR to 0.52 ± 0.31 logMAR (P < 0.05) in the MyoRing + CXL group and from
0.65 ± 0.38 logMAR to 0.62 ± 0.23 logMAR (P = 0.70) in the MyoRing group. CDVA changed
from 0.33 ± 0.19 logMAR to 0.25 ± 0.16 logMAR (P = 0.10) in the MyoRing + CXL group and 0.32
± 0.22 logMAR to 0.33 ± 0.17 logMAR (P > 0.50) in the MyoRing group. The mean keratometry
(Km) decreased from 47.5 ± 2.7 D to 43.8 ± 3.2 D (P < 0.001) in the MyoRing group and 49.3
± 3.4 D to 45.1 ± 3.0 D (P < 0.001) in the MyoRing + CXL group. Besides, horizontal coma was
significantly lower in the MyoRing + CXL group (P = 0.022).
Conclusion: MyoRing insertion combined with CXL is a safe and effective method for the
treatment of keratoconus. The visual and topographic outcomes were comparable to that for
MyoRing insertion after 10 months; however, horizontal coma was significantly lower in the
MyoRing + CXL group.
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Keratoconus is a non-inflammatory corneal ectasia
resulting in progressive thinning and steepening
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of the cornea. Patients usually present with
decreased visual acuity, progressive myopia,
irregular astigmatism, and central corneal
scarring.[1]
A wide range of options is available for the
treatment of keratoconus. In early stages,
patients can be treated with spectacles or
contact lenses. However, in advanced stages
with corneal scarring, corneal transplantation is
the only available option to restore vision. For
patients without corneal scarring intolerant to
contact lenses, the new modality, intracorneal
ring segment (ICRS) or continuous intracorneal
ring implantation in the corneal stroma may
be used. The technique of insertion of a
continuous intracorneal ring was developed in
the late 20th century with the aim of correcting
myopia. However, owing to technical difficulties
and incision-related complications, continuous
intracorneal rings were supplanted by ICRS,
which had been used to correct mild to moderate
myopia,[2–4] but recently gained great popularity
to treat keratoconus.[5–7] Although ICRS cannot
completely avert corneal transplantation, it can
delay the keratoconus progression.[8] ICRSs can
flatten the corneal center and move the corneal
apex to the center of cornea. It facilitates the
fitting of the contact lens and optimizes the best
corrected visual acuity.
The introduction of femtosecond laser
technology in the field of refractive surgery
offered new hopes to treat human refractive errors
and also provided a new surgical modality to
create tunnels for precise ICRS insertion. The
femtosecond laser-assisted ICRS implantation has
several advantages over mechanical approaches
including a more uniform dissection, less patient
discomfort, quick recovery, and more predictable
results.[9]
Corneal collagen crosslinking (CXL) uses
ultraviolet A (UVA) light and riboflavin to stiffen the
corneal stroma. The irradiation of riboflavin results
in formation of free radicals, inducing the formation
of covalent bonds between the amino acid groups
of collagen fibers.[10, 11] It halts the progression
of keratoconus as shown by several studies.[10–13]
ICRS insertion can improve the corneal topography
and correct myopia and astigmatism in keratoconic
corneas; however, it has limited effect on the
progression of keratoconus. In comparison,
as stated earlier, CXL is a safe and effective
method to stop the progression of ectatic corneal
disorders. Thus, hypothetically, the benefits of
both methods can be obtained by combining
the two procedures. Several studies have been
performed to test the safety and efficacy of the
combined procedure.[14–17] However, only few
studies have evaluated same-day ICRS + CXL. This
study was designed to assess and compare the
long-term outcome of simultaneous insertion of
MyoRing and CXL with MyoRing alone.
METHODS
This study was approved by the Institutional
Review Board of Tehran University of Medical
Sciences and was compliant with the tenets of
the Declaration of Helsinki. Informed consent was
obtained from all patients prior to the study. A
total of 60 patients aged between 18 and 35 years
who were diagnosed with keratoconus based on
the clinical and Pentacam criteria were enrolled
in this study. The inclusion criteria of the study
were keratoconic eyes with central clear cornea,
contact lens intolerance, and central corneal
thickness > 380 µm. Patients who had previously
undergone any ophthalmic surgery, pregnant
and lactating women, and those with a history
of collagen vascular diseases were excluded
from this study. Patients were randomly allocated
into two groups. In the first group, MyoRing
was implanted at a depth of 300 µm using
femtosecond laser. In the second group, MyoRing
was implanted using the same technique with
simultaneous CXL. Preoperative and postoperative
examinations included uncorrected distance visual
acuity (UDVA), corrected distance visual acuity
(CDVA), dry and cycloplegic refraction, slit lamp
biomicroscopy, dilated fundus examination,
topographic and optical pachymetry using
the Pentacam system (OCULUS, Wetzlar,
Germany), and corneal abbermotry (iTrace,
Tracey technologies, Houston, TX). Patients were
examined one day before the surgery and one
day, one month, three months, and ten months
postoperatively. The information for this trial is
available to the public through the Iranian National
Registry for Clinical Trials (http://www.irct.ir).
Surgical technique
All surgeries were done by the same experienced
surgeon (MM) at Farabi Eye Hospital, Tehran,
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Iran. The procedure was performed under topical
anesthesia using tetracaine 0.5% eye drops. The
eyes were sterilized using povidone iodine, and an
eyelid speculum was used to hold the eyes open.
The cornea was marked in the pupillary center by
a Sinskey hook as a reference point for pocket
creation. A 300 μm deep tunnel was created in
the corneal stroma using the femtosecond laser
(Technolas 520F………). The laser creates dissection
planes by focusing a 3 μm diameter laser beam
with a frequency of 500 kHz and a wavelength
of 1054 nm at a predetermined stromal depth. A
MyoRing with a diameter of 5 mm and a thickness
of 240 µm was chosen for implantation. It was then
inserted into the corneal pocket via a previously
made temporal corneal incision. In the second
group, after anesthetizing the eye and creating
the pocket, riboflavin 0.1% was injected into the
corneal pocket to completely fill it. After 5 min,
diffusion of riboflavin was observed in the corneal
stroma and anterior chamber. The MyoRing was
then implanted using the mentioned technique.
Finally, the cornea was exposed to 370-nm UVA
light for 10 min with an irradiance of 9 mW/cm2.
The MyoRing implantation and CXL procedure was
uneventful without needing sutures.
Topical antibiotic and steroid drops, and artificial
tears were used postoperatively. Chloramphenicol
0.5% was used every 4 hours for the first 10 days.
Betamethasone eye drops were prescribed for
every 2 hours after the procedure and gradually
tapered in the following three months.
Statistical analysis
Statistical analysis was performed using the SPSS,
version 21 (SPSS Inc., Chicago, IL). A P-value < 0.05
was considered as significant. Normality of data
was tested suing the Kolmogorov–Smirnov test.
The Wilcoxon rank sum test was used to compare
the postoperative and preoperative values. For
comparison of outcomes between the two groups,
the Mann–Whitney U test was performed.
RESULTS
Data of 47 eyes of 47 patients were available at the
end of the study; 28 patients in the MyoRing group
and 19 in the MyoRing + CXL group. The two study
groups were matched before treatment in terms of
age, UDVA, CDVA, pachymetry, keratometry (Km),
and higher order aberrations. Table 1 shows the
preoperative values.
Visual Outcomes
After 10 months, the mean UDVA improved from
0.79 ± 0.39 logMAR to 0.52 ± 0.31 logMAR (P <
0.05) in the MyoRing + CXL group. However, such
an improvement was not observed in the MyoRing
group. The improvement in CDVA was statistically
insignificant in both groups at the end of follow-
up. The increase in UDVA was observed after six
months in the MyoRing + CXL group.
Refractive Outcomes
Statistical analysis revealed that the spherical
equivalent (SE) improved from –6.51 ± 3 to –1.80 ±
2 in the MyoRing group (P < 0.001) after 10 months.
In the MyoRing + CXL group, the SE improved from
–6.63 ± 2.5 to –1.7 ± 2 (P < 0.001). There was a
significant improvement in Kmax in the MyoRing
+ CXL group (P < 0.05). The mean Km improved
significantly in both groups (P < 0.001).
Corneal Aberrations
The mean root mean square (RMS) total decreased
by 0.55 (P > 0.1) in the MyoRing + CXL group, while
it increased by 0.95 µm in the MyoRing group (P >
0.05). The mean RMS of higher order aberrations
(RMS HOA) increased by 0.01 in the MyoRing + CXL
group (P> 0.1) and by 0.71 µm in theMyoRing group
(P < 0.05). We also observed that the horizontal
coma decreased by 0.37 µm in the MyoRing + CXL
group (P < 0.05). Tables 2 and 3 show the visual
and topographic outcomes in the two groups after
10 months.
Comparison of MyoRing Insertion and
MyoRing Insertion + CXL
After 10 months, no significant difference was
observed in the UDVA, CDVA, and Kmax in
patients who underwent MyoRing insertion alone
and those who underwent MyoRing + CXL.
However, horizontal coma was significantly lower
in the group that underwent MyoRing insertion
associated with CXL. Table 4 compares the
refractive and visual outcomes in both groups after
10 months.
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Table 1. Mean of the preoperative data
MyoRing group MyoRing + CXL group P-value
Age 26.1 ± 4.6 24.9 ± 5.2 0.360
UDVA (logMAR) 0.65 ± 0.38 0.79 ± 0.39 0.200
CDVA (logMAR) 0.32 ± 0.22 0.33 ± 0.19 0.878
Spherical equivalent (D) –6.51 ± 3.01 –6.63 ± 2.51 0.745
Km (D) 47.5 ± 2.7 49.3 ± 3.4 0.055
K max (D) 52.4 ± 5.19 54.2 ± 4.7 0.221
Thinnest point (µm) 449 ± 41 441 ± 32 0.551
Coma horizontal (µm) 0.70 ± 0.65 0.73 ± 0.46 0.735
Coma vertical (µm) 1.39±1.07 1.19 ± 1.05 0.231
RMS HOA (µm) 2.19±1.31 2.05 ± 0.74 0.734
UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAR, logarithm of minimum of angle of
resolution; Km, mean keratometry; RMS HOA, root mean square value of total higher order aberrations in a simulated 6 mm pupil
Table 2. Change in variables in the MyoRing group after 10 months of follow-up compared to baseline
Preoperative data Postoperative 10- month data P-value
UDVA (logMAR) 0.65 ± 0.38 0.62 ± 0.23 0.710
CDVA (logMAR) 0.32 ± 0.22 0.33 ± 0.17 0.906
Spherical equivalent (D) –6.51 ± 3.07 –1.8 ± 2.11 0.001
K max (D) 52.4 ± 5.19 51.5 ± 4.1 0.312
Thinnest point (µm) 449 ± 41 452 ± 40 0.423
Coma horizontal (µm) 0.70 ± 0.65 0.99 ± 0.6 0.123
Coma vertical (µm) 1.39 ± 1.08 2.01 ± 1.11 0.021
RMS HOA (µm) 2.19 ± 1.31 2.91 ± 1.23 0.006
Complications
No complications such as migration of the MyoRing
into the anterior chamber were observed during
the surgery. As stated earlier, the procedure was
uneventful in all of the eyes, and sutures were
not needed. All eyes showed excellent tolerance
to the implanted MyoRings, and no migration or
extrusion was observed. Moreover, none of the
eyes developed corneal ulcers or stromal necrosis
superficial to the segment.
DISCUSSION
This study compared the refractive and corneal
aberrometric effect of MyoRing insertion alone and
MyoRing with concurrent CXL. As shown in the
results, combining CXL with MyoRing implantation
is an efficient method for keratoconus treatment
and can significantly decrease the Km values. It
can significantly increase the UDVA and decrease
the SE. When compared to the MyoRing group,
horizontal coma was significantly lower in the
MyoRing + CXL group; however, there was no
significant difference in other topographic and
refractive outcomes.
The main indication of CXL is to halt the
progression of ectatic corneal disorders such as
keratoconus, pellucid marginal degeneration, and
post-laser in-situ keratomileusis (LASIK) corneal
ectasia.[14, 18, 19] Collagen fibrils are crucial for
corneal stability. It has been demonstrated that
the diagonal links between collagen fibrils are
significantly reduced in keratoconic corneas.[20]
This leads to corneal thinning in central and
paracentral areas and causes myopia, irregular
astigmatism, and decreased visual acuity. CXL
stabilizes the diseased cornea by creating covalent
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Table 3. Change in variables in the MyoRing + CXL group after 10 months of follow-up compared to baseline
Preoperative data Postoperative 10- month data P-value
UDVA (logMAR) 0.79 ± 0.39 0.52 ± 0.31 0.034
CDVA (logMAR) 0.33 ± 0.19 0.25 ± 0.16 0.118
Spherical equivalent (D) –6.63 ± 2.51 –1.70 ± 2.41 0.001
K max (D) 54.2 ± 4.71 52.1 ± 3.75 0.032
Thinnest point (µm) 442 ± 39 445 ± 51 0.623
Coma horizontal (µm) 0.73 ± 0.46 0.37 ± 0.31 0.033
Coma vertical (µm) 1.91 ± 1.14 1.62 ± 1.42 0.081
RMS HOA (µm) 2.05 ± 0.74 2.06 ± 0.18 0.878
Table 4. Comparison of parameters in the MyoRing and MyoRing + CXL groups after 10 months
MyoRing MyoRing + CXL P-value
UDVA (logMAR) 0.62 ± 0.23 0.52 ± 0.31 0.174
CDVA (logMAR) 0.33 ± 0.17 0.25 ± 0.16 0.105
Spherical equivalent (D) –1.8 ± 2.11 –1.70 ± 2.41 0.920
Km (D) 43.8 ± 3.2 45.1 ± 3.0 0.137
K max (D) 51.5 ± 4.1 52.1 ± 3.75 0.346
Thinnest point (µm) 452 ± 40 445 ± 51 0.688
Coma horizontal (µm) 0.99 ± 0.6 0.37 ± 0.31 0.022
Coma vertical (µm) 2.01 ± 1.11 1.62 ± 1.42 0.661
RMS HOA (µm) 2.91 ± 1.23 2.06 ± 0.18 0.896
bonds (cross links) between the collagen fibrils.
It stops the progression of keratoconus without
considerably changing the shape of the cornea.
MyoRing implantation, on the other hand, can
treat keratoconus by inducing a flattening effect,
without affecting the underlying pathophysiology
of ectasia. Therefore, combining CXL with MyoRing
implantation would hypothetically stabilize the
progression of keratoconus and improve the
visual acuity by flattening the cornea. There are
limited studies evaluating the outcome of MyoRing
implantation with simultaneous CXL.
CXL, which has been used for treating
keratoconus since 1990s, is believed to be
the only treatment that can halt the progression
of keratoconus. In this procedure, UVA light is
irradiated to the cornea after treatment with
riboflavin solution, resulting in formation of free
radicals and inducing covalent bonds between
amino groups of the collagen molecule, thus
increasing the biomechanical stability of the
cornea.[21, 22] In this study, we used a rather new
technique for CXL; riboflavin 0.1% solution was
injected into the corneal pocket created by the
femtosecond laser, followed by exposing the
cornea to UVA light for 10 min. The corneal
epithelium is usually removed before the UV
light is irradiated to the cornea to allow adequate
penetration of riboflavin into the corneal stroma.
Simultaneous introduction of riboflavin 0.1% into
the corneal pocket created by the femtosecond
laser obviates the need for epithelial debridement
and reduces pain and discomfort in the early
postoperative period.[23, 24] However, the corneal
stroma composed of tightly compacted collagen
fibers is fairly resistant to molecular transport. The
stromal barrier can be eliminated by injecting the
riboflavin solution directly into the pocket, allowing
more uniform distribution in the corneal stroma.
Dextran was not present in the solution as corneal
toxicity might occur when it is directly injected
into the corneal stroma. It has been demonstrated
that a cross-linked cornea is less clear compared
to a virgin cornea. Therefore, femtosecond laser
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penetration into the corneal stroma may be less
effective in eyes that underwent CXL. El Raggal
found that channel creation by femtosecond laser
is more challenging in eyes that had undergone
CXL. They attributed this effect to the possible
rigidity of collagen fibers in the deep corneal
stroma in patients treated by CXL.[25] Femtosecond
laser energy can be increased to overcome this
problem; however, this solution may lead to a
persistent corneal reaction, postoperatively.[25]
The keratoconic cornea is a highly aberrated
cornea with significantly more coma and coma-
like aberrations compared to the normal eye.
In this study, horizontal coma was significantly
lower in eyes that underwent MyoRing implantation
with simultaneous CXL. Thus, combining CXL
with MyoRing implantation might enhance the
flattening effect of the segment without inducing
considerable HOA. Furthermore, a synergistic
effect might also be present, when CXL is
combined with ICRS implantation, augmenting the
therapeutic effect that is observed with either
treatment.[15]
Hafez recently studied the outcomes of KeraRing
and MyoRing implantation with simultaneous
CXL.[15] Patients who underwent MyoRing
implantation plus CXL showed a significant
reduction in Kmean. However, there was little
improvement in the astigmatic component of
keratoconus with MyoRing implantation, and
significant reduction of astigmatism was observed
in patients treated by combination of KeraRing and
CXL.
In a retrospective study by Bikbova et al, the
efficacy of MyoRing implantation and MyoRing
implantation + CXL after three years was reported.
They found that MyoRing implantation with
simultaneous CXL had slightly better outcomes,
although the effect of MyoRing implantation
alone was stable over time.[26] Similarly, in this
study, we found that the topographic and visual
outcomes were comparable in the two groups
after 10 months, although horizontal coma was
significantly lower in patients who underwent
MyoRing implantation with simultaneous CXL.
El Raggal evaluated the outcome of combined
KeraRing insertion with CXL, performed in a single
session or with a six-month interval. He observed
that there was a significant improvement in UDVA,
CDVA, and keratometric values. However, patients
treated using the same-day method had better
topographic outcomes.[27]
Coskunseven and colleagues found that ICRS
implantation followed by CXL is more effective
in improving CDVA, SE, and the mean Km in
keratoconus compared to CXL followed by ICRS
implantation. The mean interval between the
treatments was seven months.[28]
None of the patients during the study developed
segment decentration and extrusion, partly due to
application of femtosecond laser, which creates a
more precise depth of incision.
Despite the limited number of cases, this study
shows that the MyoRing + CXL procedure is a
safe and effective method for treating keratoconus.
It is comparable to MyoRing insertion alone for
improvement in visual and topographic outcomes
in the short term. Moreover, a significant reduction
in HOA is observed with the MyoRing + CXL
procedure, which is of paramount importance in
highly aberrant corneas with keratoconus. More
studies with a longer follow-up are needed to
better elucidate the efficacy and safety of this
procedure.
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